← FDA DRUG APPROVALS

FDA ANDA · ANDA090884

AMPICILLIN SODIUM

Sponsor: ACS DOBFAR SPA

APPLICATION
ANDA090884
TYPE
ANDA
ORIGINAL APPROVAL
2013-04-03
LATEST ACTION
2024-05-01
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMDiscontinued
AMPICILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-05-01Labeling · Supplement 3 · standardAP
2018-01-30Labeling · Supplement 2 · standardAP
2018-01-30Labeling · Supplement 1 · standardAP
2013-04-03OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →